Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 8, 15–16 (1 January 2009) | doi:10.1038/nrd2758
Do molecularly targeted agents in oncology have reduced attrition rates?
&
Abstract
Attrition rates are a critical issue in drug development, especially within oncology, in which rates have been reported to be relatively high. Indeed, some figures suggest that clinical attrition rates are as much as fourfold higher in oncology than in other indications.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
